Court Sets Terms For Pfizer Damages Over Axed Lyrica IP

By Joanne Faulkner ( July 30, 2021, 5:57 PM BST) -- The money the National Health Service and generic drug companies can claim back from Pfizer over an invalidated epilepsy drug patent should be assessed based on how much money they would have made if subsidiary Warner-Lambert had not threatened any infringement proceedings, a judge ruled Friday in London. ...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!